Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 4, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. Investors can dial 866-595-4538 for domestic or 636-812-6496 for international access, using conference ID 4472467. A replay will be available for 30 days post-event. Syros is focused on developing treatments that modulate gene expression, with a clinical-stage pipeline that includes innovative therapies like SY-1425 for myelodysplastic syndrome and SY-5609 for solid tumors.
- Syros is advancing a robust clinical-stage pipeline with multiple innovative therapies.
- The upcoming financial results may provide insights into the company's performance and future growth.
- No specific financial metrics or guidance were provided in the PR.
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter and full year 2020 financial results and provide a corporate update.
To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 4472467. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005007/en/
FAQ
What are the financial results for Syros Pharmaceuticals for Q4 2020?
What is the significance of the conference call on March 4, 2021, for SYRS investors?
What is the main focus of Syros Pharmaceuticals?
What therapies are included in Syros' clinical pipeline?
